A detailed history of Cetera Investment Advisers transactions in Cassava Sciences Inc stock. As of the latest transaction made, Cetera Investment Advisers holds 42,554 shares of SAVA stock, worth $102,555. This represents 0.0% of its overall portfolio holdings.

Number of Shares
42,554
Previous 37,890 12.31%
Holding current value
$102,555
Previous $467,000 168.09%
% of portfolio
0.0%
Previous 0.0%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$9.57 - $35.08 $44,634 - $163,613
4,664 Added 12.31%
42,554 $1.25 Million
Q2 2024

Aug 22, 2024

BUY
$12.35 - $26.11 $223,633 - $472,799
18,108 Added 91.54%
37,890 $467,000
Q1 2024

May 24, 2024

BUY
$18.44 - $26.41 $364,780 - $522,442
19,782 New
19,782 $401,000

Others Institutions Holding SAVA

About CASSAVA SCIENCES INC


  • Ticker SAVA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 40,097,900
  • Market Cap $96.6M
  • Description
  • Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's...
More about SAVA
Track This Portfolio

Track Cetera Investment Advisers Portfolio

Follow Cetera Investment Advisers and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cetera Investment Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Cetera Investment Advisers with notifications on news.